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Abstract
Maternally mitochondrial dysfunction includes a heterogeneous group of genetic disorders which leads to the impairment of the
final common pathway of energy metabolism. Coronary heart disease and coronary venous disease are two important clinical
manifestations of mitochondrial dysfunction due to abnormality in the setting of underlying pathways. Mitochondrial dysfunc-
tion can lead to cardiomyopathy, which is involved in the onset of acute cardiac and pulmonary failure. Mitochondrial diseases
present other cardiac manifestations such as left ventricular noncompaction and cardiac conduction disease. Different clinical
findings frommitochondrial dysfunction originate from different mtDNAmutations, and this variety of clinical symptoms poses
a diagnostic challenge for cardiologists. Heart transplantation may be a good treatment, but it is not always possible, and other
complications of the disease, such as mitochondrial encephalopathy, lactic acidosis, and stroke-like syndrome, should be
considered. To diagnose and treat most mitochondrial disorders, careful cardiac, neurological, and molecular studies are needed.
In this study, we looked at molecular genetics of MIDs and cardiac manifestations in patients with mitochondrial dysfunction.
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Abbreviations
ANT Adenine nucleotide translocator
BSCL2 Berardinelli-Seip congenital lipodystrophy
CMP Cardiomyopathy
COX Cytochrome c oxidase
ECMP Encephalocardiomyopathy
MELAS Mitochondrial encephalopathy lactic acidosis
and stroke-like episodes
MERRF Myoclonus epilepsy red ragged fibers
MID Mitochondrial dysfunction
MRP Mitochondrial ribosomal protein
MTO Mitochondrial tRNA translation optimization
ND1 NADH-ubiquinone oxidoreductase chain 1
NDUFAF1 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex assembly factor 1
OXPHOS Oxidation-phosphorylation
ROS Reactive oxygen species
Introduction
Mitochondria are involved in various fundamental cellular pro-
cesses like apoptosis, calcium signaling, and generation of reac-
tive oxygen species (ROS), but the most principal action of
mitochondria is the synthesis of adenosine triphosphate (ATP)
through oxidative phosphorylation pathway. Electron transfer
between respiratory chain enzymes occurs through an electro-
chemical slope in the inner mitochondrial membrane [1, 2].
Defects in the oxidative phosphorylation pathway cause a
variety of diseases ranging from the involvement of one tissue
to the involvement of multiple organs with high-energy de-
mands such as the heart and brain. Mutations or gene variation
can play a role in the onset and severity of the disease [3, 4].
Mitochondrial DNA in neonatal heart cells has a simple, amor-
phous and double-stranded structure. Branched forms appear in
adults as mitochondrial DNA copy number increases in early
childhood [5]. Adult humanmitochondrial DNA has a complex
organization with a large number of dimer molecules, four-way
junction, and branching structures [6].
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In adults, mtDNAmutations are the most common cause of
mitochondriopathy or mitochondrial dysfunction (MID).
More than 300 mtDNA have been recognized so far. The
number of mtDNA molecules in the oocyte is remarkably
diminished during the development of the female germ cells
before re-amplification to final count (less than 100,000) [7].
The ratio of mutated to normal mtDNA can change over time,
affecting the prevalence and severity of the disorder. Thus
inter-genetic shifts in mtDNA mutation with subsequent var-
iation in clinical disease severity are due to this germ cell
bottleneck [8]. Due to the deficiency of DNA repair mecha-
nisms and proximity to the OXPHOS system, 10–17-fold mi-
tochondrial mutations higher than nuclear DNA mutations
result in MIDs [9, 10].
Cellular OXPHOS dysfunction due to primary genetic de-
fects (mitochondrial or nuclear DNA) leads toMIDs [11]. The
precise extent and range of MIDs in the general population
have yet to be determined [12]. The actual prevalence of these
defects is underestimated, probably due to regional referral
patterns. In the general population, there is a 1/300 G
m.3243A>G mutation [13]. Diseases related to mtDNA mu-
tation appear to be more common than previously thought
(about 1/5000) because many people may have low mutation-
al burden and are asymptomatic [14]. In a broad spectrum of
MIDs, point mutations in mitochondrial DNA have been iden-
tified. Increasing the mutant mtDNA ratio (60–90%) affects
the MID and its onset and severity. A small fraction of the
mitochondrial genome (< 1%) is mutated in the general
populatio. [15]. There are different phenotypes of MID, but
one of their main features is heterogeneity due to the presence
of both normal and mutant mtDNA in the cell population [16].
In cardiac muscle cells, mitochondrial number, topological
arrangement, and replication mode are linked together [8].
By now, more than 250 pathogenic mtDNAmutations have
been identified which many are associated with cardiac mani-
festations. Maternally transmitted MIDs comprise a heteroge-
neous group of genetic disorders that disrupt the pathway of the
final metabolism of energy production. The major components
of the respiratory chain are affected by mitochondrial DNA
mutations, which include most for a majority of mitochondrial
DNA deletion syndromes. Clinical presentations of MIDs are
varied from oligo-symptomatic (migraine, type 2 diabetes
mellitus (DM)) to very complex syndrome [10]. In summary,
clinical phenotype of MIDs include mitochondrial encephalop-
athy, lactic acidosis and stroke-like episodes (MELAS), myoc-
lonus, epilepsy, red ragged fibers (MERRF), Leber hereditary
optic neuritis with acute or sub-acute visual loss), Leigh (sub-
acute necrotizing encephalopathy and basal ganglion lesions),
mitochondrial myopathy-cardiomyopathy, Wolfram syndrome
(diabetes insidious, optic atrophy, and deafness), and Pearson’s
marrow pancreas syndrome (sideroblastic anemia, exocrine
pancreatic insufficiency, hepatopathy, and nephropathy) [17,
18]. Expression and segregation of mitochondrial diseases are
different from nuclear genemutations. Mitochondrial gene mu-
tations can be heterogeneous or homogeneous and cause a
disease phenotype when mutations exceed threshold levels.
Often, there is a correlation between the rate of mutation and
the expression of the disease phenotype, and sometimes differ-
ent mutations occur in different tissues [3]. Some pathways in
the pathogenesis of MID-induced cardiac disorders are also
observed in the natural aging process by increased cardiac mi-
tochondrial ROS and decreased mitochondrial and nuclear
DNA integrity [19, 20].
Mitochondrial genetics
Mitochondria have been implicated in important cellular pro-
cesses such as apoptosis and calcium signaling, but cellular
respiration and adenosine triphosphate (ATP) synthesis is their
main function. ATP production is accomplished by the elec-
trons transmission between the respiratory chain enzymatic
complexes and transfer of proton into the mitochondrial inner
membrane and the creation of an electrochemical gradient. As
well as 13 import polypeptides of the OXPHOS enzyme com-
plexes, the mitochondrial genome encodes 22 transfer RNA
(mt-tRNA) and two ribosomal RNA (mt-rRNA). Other struc-
tural and functional proteins of mitochondria are expressed by
the nucleus genome. The mitochondrial genome has unique
features and complex inheritance. The maternal inheritance of
mitochondrial DNA differs from that of the Mendelian model
of nuclear DNAmutations. There are several copies of mtDNA
in each cell, and a small percentage of them may have a muta-
tion. The rate and threshold of mtDNA mutation may affect
clinical disease incidence and extent [21]. The identification
of pathogenic mtDNA mutations, that commonly result in iso-
lated organ phenotypes such as cardiomyopathy (CMP), re-
veals the fact that other genetic (e.g., expression of
aminoacyl-tRNA synthetase) or environmental factors can
modulate the phenotype [22, 23]. Since the inheritance of hu-
man mitochondrial diseases is purely from the mother’s side,
the presence of the disease in maternal relatives increases the
suspicion of mitochondrial disease, so diagnosis through genet-
ic counseling is quite different from nuclear genetic diseases
[24]. Depending on the type of mutation, the probability of
transfer from mother to child varies. Large and single deletions
are less likely to be transmitted, while point mutations are more
likely to be inherited from mothers. The number of mtDNA in
each oocyte decreases greatly during the development of female
germ cells. The variation in the severity of hereditary diseases
can partly be explained by this “genetic bottleneck” and change
in the rate of mtDNA mutation across generations [25]. The
percentage of mutations in the mitochondrial genome is higher
than that of the nuclear genome due to a lack of DNA repair
mechanisms. High levels of mtDNA mutation in patients can
lead to clinical progression of the disease. The ability of
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continuous replication causes mutant mtDNA molecules to in-
crease with colonic proliferation even after mitosis of cells,
including cardiomyocytes [15, 24].
Epigenetic in MIDs
Alongside with genetic alterations, epigenetic modifications,
i.e., DNA methylation, histone modifications, and noncoding
RNAs have very important roles in various disorders such as
cancer, diabetes, viral infections, and the cardiac complica-
tions due to mitochondrial diseases. Like nuclear DNA,
mtDNA, can be methylated by mechanisms present within
mitochondria. Epigenetic patterns of mtDNA may vary by
tissue and cell type, because the number of mitochondria
and their activity in different cells varies [26]. However, low
levels of mtDNA methylation and low sensitivity to conven-
tional measurement methods have questioned the effective-
ness of using mtDNA methylation as a biomarker. However,
sensitive techniques, including the bisulfite pyrosequencing,
are used to measure mtDNA methylation levels [27, 28].
Recently, mitochondrial DNA methylation has been investi-
gated in many genes, including MT-ATP6, MT-APT8, MT-
ND2, MT-ND4, MT-ND5, MT-ND6, MT-CO1, MT-CO2,
and MTCO3. These genes encode effective molecules and
enzyme in the electron transport chain such as ATP synthesis,
NADH dehydrogenase, and cyclooxygenase [29, 30].
Baccarelli et al. also showed that the level of methylation of
several mitochondrial genes in people with CVD is higher
than in healthy people. Furthermore, the expression of leucine
1 (MT-TL1) tRNA gene in CVD patients is different from that
in healthy people. Therefore examination of mitochondrial
gene methylation in platelets and blood cells can be consid-
ered as a biomarker in people at risk for CVD [29].
Noncoding RNAs are very important classes of epigenetic
regulators that play crucial roles in different diseases [31–36].
MicroRNAs (miRNAs) are short noncoding single-stranded
RNA molecules that epigenetically regulate gene expression
after transcription by destroying or inhibiting mRNA translation
[37–40]. It has been showed that deregulation of miRNAs are
associated with several disorders such as various cancers, and
cardiovascular diseases [41–45]. About 150 miRNAs have been
detected in mitochondria so far, but the characteristics and per-
formance of many of them are not well known [46]. Among
them, miR-23a, miR-23b, miR24, miR-92 miR-103, miR-106a,
miR-125a, miR-125b, miR-133, miR-193, miR-221, miR-365,
and miR-423 are some better-known microRNA in mitochon-
dria [47]. Mitochondria dysfunction can cause cell damage by
producing active oxygen species (ROS), which is abundant in
the CVD. Various miRNAs are involved in endothelial and
vascular dysfunction and CVD through oxidative stress and
overproduction of ROS. Some miRNAs can regulate the
OXPHOS in mitochondria by affecting molecules in electron
transfer and ATP production. Recent studies indicated that com-
plexes III, IV, and V in mitochondria are inhibited by miR-210,
miR-181c, and miR-141, respectively [48]. It has also been
shown thatmiR-181c has a role in the remodeling of the electron
chain complex IV in rat cardiomyocytes [49]. In
cardiomyocytes, miRNAs interfere with the mitochondrial net-
work by regulating Mfn1. In adult cardiac myocytes, mitochon-
drial fusion is essential for maintaining mitochondrial morphol-
ogy and for normal contractile and respiratory function [50].
Cardiac involvement in MIDs
Cardiac involvement (CI) is one of the major problems of
MIDs, but cardiologists rarely consider these defects in the
etiology of heart disease. The prevalence of cardiac involve-
ment in MIDs is due to the complete dependence of the heart
on oxidative metabolism and may occur as a major clinical
complication or part of a multi-systemic disease [51]. The
incidence of mtDNA carriers’ mutations and at-risk individ-
uals for the mitochondrial disease was estimated at 1:10,000
adults [17]. The importance of diagnosing CI in MIDs is be-
cause earlier diagnosis helps better treatment. Studies have
shown that life expectancy in CI patients is significantly re-
duced if MID is present. This is because the supply of energy
to the heart is the same as the muscle and the brain depends on
aerobic respiration [52]. Organs such as the heart that have
high aerobic metabolism are more susceptible to damage
caused by MIDs. Continuous pulse causes cardiomyocytes
to need more energy than skeletal muscle and differences in
respiratory ratios [53, 54].
Myocardial abnormalities
Cardiomyopathy (CMP) is a major cardiac problem of mito-
chondrial disorders (MIDs) that divided into restrictive, hy-
pertrophic, dilated, and unclassified CMP. The hypertrophic
CMP (hCMP) is the most common cardiac abnormality in
MIDs (Table 1). Some syndromic MIDs include Leigh-syn-
drome, MERRF, MELAS, NARP, and CPEO are associated
with hCMP, (Table 2).
Coronary artery disease
Coronary artery disease (CAD) might occur due to coronary
abnormalities mainly in small vessels which have been report-
ed rarely in the setting of MIDs but angina due to these coro-
nary involvements have not been yet reported [122]. C3256T
heteroplasmy level, as a biomarker of MID, is a predisposing
factor for atherosclerosis, coronary artery disease, and myo-
cardial infarction [11]. Indeed, CAD may be caused by the
simultaneous presence of classical risk factors for heart
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diseases such as DM, hypertension, hyperlipidemia, or ciga-
rette smoking independently or MID dependent. Among en-
docrine problem, DM is more common while hepatic, renal,
and other endocrine disorders are rare [123–125]. Renal im-
pairment is seen in MELAS, MERRF, Pearson syndrome,
Leigh syndrome, and kerns Sayre syndrome (KSS) [126]. In
a study, DM, arterial hypertension, atherosclerosis, pulmonary
hypertension, hyperlipidemia, and severe cardiac diseases
were reported in a 72-year-old woman with MID.
Apparently, after the occurrence of an acute coronary event,
MID has been involved in the development and progression of
ischemia/reperfusion (I/R) injury [127, 128].
Cerebrovascular disease
A stroke in myopathies is often with cardio-embolic origin
which may be due to atrial fibrillation/flutter or dilated
Table 2 Cardiac abnormalities and affected gene in MIDs
Cardiac abnormality Involved gene Ref
Myocardial fibrosis arrhythmias mtDNA deletion [81]
Systolic dysfunction heart failure ND5 [82]
Leu-tRNA [83]
Sinus arrhythmia Leu-tRNA [84]
AFIB/AFLU mtDNA depletion [85]
Ventricular tachycardia Leu-tRNA [86]
Single mtDNA deletion [87]
AV block Leu-tRNA [88]
Single mtDNA deletion [81]
Restrictive cardiomyopathy ND5 [2] [89]
mtDNA deletion [90]
Sudden cardiac death Lys-tRNA [91]
Leu-tRNA [92]
Bundle branch block Leu-tRNA [93]
Single mtDNA deletion [94]








Non compaction Cyt b [102]
ND1 [103]





QT prolongation Single mtDNA deletion [107]







Single mtDNA deletion [112]
Ventricular cavity obstruction 12sRNA, ND1, ND4, ND6 [113]
Ventricular septal defect mtDNA depletion [114]
Hypoplastic left heart syndrome mtDNA depletion [114]
Autonomic nerve fibers Leu-tRNA [115]
Dilation of aortic root mtDNA deletion, depletion [116]
Noonan syndrome MYBPC3 [113]
Patent foramen ovale BSCL2 [66]
DNA2 [117]
Leu-tRNA [118]
Coronary heart disease Thr-tRNA [119]
Pericardial effusion HDHA, HDHB [120]
Lys-tRNA [121]
Autonomic nerve fibers Leu-tRNA [86]
Table 1 Phenotypes of mitochondrial and nuclear gene mutation
Gene/defect Phenotype Ref
mtDNA
ATP 8 hCMP, neuropathy [55]
ND1 Variable [56]
ND5 Leigh syndrome, hCMP [57]
12s RNA Variable [51]
rRNA hCMP [58]
Leu-tRNA hCMP, infantile CMP [59]
Gly-tRNA Infantile CMP [60]
Val-tRNA Variable [51]
Lys-tRNA NS, variable [61]
nDNA
Ala-tRNA synthesize Infantile CMP [62]
ANT1 CMP, myopathy [63]
ATPase 8 Infantile CMP [64]
ATP synthesize ECMP [65]
BSCL2 Generalized lipodystrophy [66]
COX3 Variable [67]
MRPS 22 NS, ECMP [68]
MRPL44 Infantile CMP [69]
MRPL3 CMP [70]
MTO1 hCMP, lactic acidosis [71]
NDUFAF1 Infantile CMP [72]
NDUFS2 Leigh syndrome [73]
NDUFV2 Early-onset hCMP [74]
NFU1 Infantile encephalopathy [75]
RCC1 mutation Syndromic MIDs, NS [76]





cardiomyopathy of the left ventricular noncompaction [129,
130]. Low-flow infarcts can be caused by severe heart failure
due to cardiomyopathy. Angiopathy from atherosclerosis or vas-
culitis is the second most frequent cause of stroke in myopathies
as a factor of inflammatory myopathies [131–133]. Stroke-like
episodes often occur in mitochondrial encephalopathy, lactic
acidosis, and stroke-like episode syndrome and are rarely seen
in Leigh syndrome and other MIDs. Stroke-like episodes can be
a manifestation of metabolic or vascular processes and are dif-
ferent from ischemic strokes [134]. The neurological symptoms
of MELAS are due to respiratory chain deficiencies (RCD) re-
lated to vascular cytochrome c oxidase deficiency. RCD could
present in various clinical manifestations. Minimizing substrate
deficiencies in RCD by pharmacological supplement such as
coenzyme Q10 could be useful [135, 136].
Cardiomyopathy
Cardiomyopathies (CMPs) are a wide genetically and clinical-
ly heterogeneous group of cardiac disorders with primary in-
volvement of myocardial tissue [137]. MIDs are known as the
second most common cases of CMPs. Infantile cardiomyop-
athies are disastrous disorders of the neonatal period and first
year of life. MID is a common cause of this disease entity.
However, gene defect have been recognized in a small pro-
portion of these patients [62]. The exact prevalence of MID-
related CMP is unknown. CMP may be the only complication
or one of the problems. CMPmay be the only complication or
one of the symptoms. In patients with idiopathic primary car-
diomyopathy, specific mtDNA mutation has been identified
[138]. Senescent mitochondria often have large size, defect in
ATP synthesis, high ROS production, and reduced inner
membrane potential. In end-stage mtDNA-related CMPs, re-
markable induction of mitochondrial biogenesis with a detri-
mental effect on cardiomyocytes is observed [139, 140].
However, adverse cardiac remodeling is attributed to the pro-
liferation of mitochondrial inter-myofibrils which interferes
with the sarcomere function [140–142]. Oxygen consumption
is enhanced in mitochondrial-related CMPs due to the induc-
tion of genes participating in mitochondrial biogenesis [54].
This is in contrast with other pathogenesis such as left ventric-
ular hypertrophy (LVH) in which energy metabolism is
shifted from free fatty acid (FFA) to glucose oxidation
[143]. In the absence of antioxidants, mutations in mitochon-
dria lead to ROS generation. Also, the role of ROS in muta-
tions in nuclear genes is well known, but mtDNA mutations
have not yet been confirmed [144, 145]. Cardiomyopathy is
an important clinical manifestation of Refsum disease. In this
disease, phytanic acid accumulates in tissues and biological
fluids, but pathophysiological mechanism of heart damage is
poorly understood. Disturbance of cellular energy and redox
hemostasis induced by phytanic acid are likely to contribute to
the development of cardiomyopathy in Refsum disease [146].
Heart failure (HF) is the end stage of all CMPs, but it could
be attributed to some specific genetic disorders. In one study
of untreated patients with Barthes syndrome, HF or septicemia
was the leading cause of death. Left-sided dilation and hyper-
trophy or both are seen in boys [147]. Myocardial fibrosis and
combination of circular and tubular crista and spherical mito-
chondria were seen under electronmicroscopy examination of
myocardial tissue [146]. Formation and destruction of recently
described inter-mitochondrial junction (IMJ) are involved in
compensatory adaptive reactions. An animal study demon-
strated that an overload of heart decreased the number of
IMJs or completely destroyed the IMJs and mitochondria,
leading to acute heart failure and death [148]. Pulmonary hy-
pertension can develop in long-standing CMPs but may also
occur initially. Persistent pulmonary arterial hypertension in
the newborn apical hypertrophic cardiomyopathy is a rarely
reported manifestation associated with mitochondrial dys-
function associated with TMEM70 deficiency even in the ab-
sence of overt cardiomyopathy and represents an early sign for
the diagnosis [149].
Left ventricular hypertrophy and hypertrophic
cardiomyopathy
Normally, the energy needed for the heart to function is ob-
tained from the breakdown of fatty acids [150]. Various mol-
ecules such as glucose, pyruvate, ketone bodies, and FFA
produce energy in various metabolic processes. In some path-
ological conditions, heart changes its source of energy produc-
tion from FFA to glucose and pyruvate similar to the fetal
period. In the hypertrophic heart, the role of glycolysis in
energy production is higher. Heart functional overload such
as myocardial hyper-functioning provides adequate energy
supplies through mitochondrial hyperplasia and IMJ forma-
tion [151, 152]. Hypertrophic remodeling is reported in
myocytes of patients with MIDs which mimics hypertrophic
cardiomyopathy (HCM). Since MID is a potential cause of
HCM, cardiologists should differentiate these disease through
presence of noncardiac symptoms and maternal inheritance.
The main point mutation related to HCM is TMEM70 which
is the most common cause of nuclear ATP synthesis deficien-
cy [153]. In cases harboring m.3243A>Gmutation, the rate of
LVH has been reported to be 38–56%. There is a correlation
between LV mass and skeletal muscle mutation load. CMP is
the result of both sporadic and maternally inherited point mu-
tations in mtDNA [86, 154]. LVH may be a cardiac sign of
mutations in other than mtDNA gene such as mt-RNA genes
(m.8344A>G in MTTK, m.4264A>G and m.4317A>G in
MTTI) or polypeptide genes (m.8993T>G and m.8528T>C
in MTATP6/MTATP8 overlap regions) [10, 98]. mt-RNA
genes are sensitive to mutations related to hypertrophic geno-
type. Mutations in mt-RNA and polypeptides are common in
development of LVH. In cardiac diseases, homoplasmic
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mtDNA mutations with organ-specific phenotypes such as
m.4300A>Gmutations inMTTI gene in patients with isolated
mtDNA-related cardiomyopathy have been reported. The
likelihood of progression to LV dilation and HF in mtDNA-
related LVH is higher than hypertrophic cardiomyopathy. In
individuals harboring m.3243A>G mutation, degree of LVH
is positively related to chamber dilation and negatively with
cardiac systolic function. Mutations in m.3343A>G or
m.8344A>G are related to both HF and LV systolic dysfunc-
tion in patients with LVH [10, 98]. Left ventricular outflow
tract obstruction and apical hypertrophic cardiomyopathy
have also been reported with regard to MIDs. In taken biopsy
samples from affected hearts, red ragged fibers are seen. HCM
is most commonly seen as a feature of KSS and in association
with atrioventricular block which is attributed to a single
large-scale defect in mtDNA. Leigh’s syndrome is occasion-
ally manifested by hypertrophic cardiomyopathy and asym-
metric septal hypertrophy [10, 92].
CMP is a life-threatening presentation of Friedreich ataxia
(FA). FA is a genetic disorder of the central nervous system
with cardiac involvement and endocrine disturbance in some
cases. Cardiac involvement is a major determinant of the FA
disease that is the most mortal complications of the disease.
Up to 20% of cases with FA are conflicted by cardiac disor-
ders [155]. Unstable GAA nucleotides repeat expansion (>
120 repeats) in the primary intron of the frataxin gene (9q13)
in both alleles lead to the development of FA, as autosomal
recessive disorder manifested mainly as spinocerebellar de-
generation [156].
Cardiac involvement is a major determinant of the FA dis-
ease. Although cardiac involvement is usually followed by
degeneration of the nervous system, it is not a secondary dis-
ease and is not associated with the severity and duration of
neurological diseases [157].
The most common recognized cardiac involvement in FA is
concentric LVH [156]. Intraventricular septal hypertrophy and
frataxin repeat length in smaller alleles is remarkably correlated.
Indeed, the septal to posterior wall thickness ratio is highly re-
lated to GAA repeat size on the smaller alleles. Degree but not
the severity of LVH is correlated to GAA repeat size in smaller
allele [158]. LV mass index is diminished by age in the setting
of FA. Thus, hypertrophy would be seen in a minority of adult
patients with FA. These cardiac manifestations are attributed to
deficiency of the frataxin, a mitochondrial protein which its
sufficient amounts are required for maintenance of proper cellu-
lar iron hemostasis [159]. In some cases, no cardiac symptom
could be established and cardiac involvement could be detected
just by electrocardiography (ECG) and echocardiography eval-
uation. For accurate assessment of cardiac anatomy in FA, mag-
netic resonance imaging is recommended [127, 160]. Rarely,
mitral valve prolapse without LVH is seen in cases with FA
[129]. MELAS syndrome is a multi-organ disease that usually
begins in early childhood and was first described in 1984 by
Pavlakis et al. The disease characterized by red ragged fiber
(RRF) on muscle biopsy and hemiparesis, seizure, hemianopia,
cortical blindness, lactic acidosis, short stature, and normal early
development [161]. A common point mutation of mitochondrial
myopathy is stroke-like lactic acidosis encephalopathy with a
transmission of A to G at 3243 of untranslated reign (UTR) of
RNA [162]. Mitochondrial microangiopathy has not been re-
ported in cardiac rather than cerebral manifestation of MELAS
syndrome. Mutations in Lucine tRNA (3243 positions) is re-
sponsible for 80% of cases with MELAS syndrome [163].
Echocardiographic evaluation shows an initial abnormal thick
of left ventricle wall progressing to severe dilation and poor
ventricular contraction [164].
Dilated cardiomyopathy Dilated cardiomyopathy (DCM) in
MIDs is most commonly due to pre-existing hypertrophy as
a late phenomenon [165]. Lack of data about the history of
patients withMIDs and DCMPmay be due to the rarity of this
phenotype. Due to progressive skeletal myopathy and restrict-
ed physical activity, cardiac symptoms are limited in cases
with multi-systemic MIDs. DCM is also seen in Barth syn-
drome, an X-linked recessive syndrome, with neutropenia and
skeletal myopathy [166] . Alcoholic CMPwhich is manifested
as DCM has been reported to be linked with acquired MID.
The most prominent feature of alcoholic CMP is the mega-
mitochondrial formation by the fusion of dilated crista.
Swollen mitochondria with disorganized crista directly related
to decreased activity of oxidative phosphorylation system and
suppression of ATP synthesis [167].
Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCMP) is the only sign of mu-
tation in the m.1555A>G mt-rRNA gene [168]. MID-related
RCMP is associated with m.3243A>G mutation and is the
mere manifestation of m.1555A>G mutation [10].
Histiocytoid CMP is characterized by the pathogenic
histiocyte-like cells within sub endocardium and aggregation
of structurally abnormal mitochondria, linked to m.8344A>G
mutation in MTCYB gene which encoded complex III en-
zyme subunit [10]. Fabry disease is a rare lysosomal storage
disorder with X-linked recessive inheritance that results from
a deficiency of alpha-galactosidase as a lysosomal enzyme.
Deficiency of this enzyme leads to accumulation of
globotriaosylceramide (GL-3) in vascular and endothelial tis-
sues, which one of the symptoms can be RCMP. Thus, mito-
chondrial cytopathic disorders involve several organs but
heart failure may not occur in childhood [10, 169].
Left ventricular noncompaction
Abnormal myofibril compaction during cardiogenesis leads to
left ventricular noncompaction (LVNC). LVNC is one of the
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cardiac manifestations in MIDs particularly in the pediatric
population [170]. LVNC has been reported in adults with
m.3398T>C mtDNA variants [138].
Electrocardiographic abnormalities
In patients with MIDs, electrocardiographic (ECG) abnormal-
ities as prolongation of QTc (> 440ms), widening of corrected
QRS interval, bundle branch block, premature atrial and ven-
tricular contraction, and wolf Parkinson white syndrome have
been reported [171]. ECG abnormalities have also been re-
ported in cases with MERRF syndrome [102]. Thus, active
screening with ECG has been suggested in patients withMIDs
even in cases without overt cardiac manifestations [135].
Cardiac conduction disease
The prevalence of cardiac conduction disease in MIDs in-
creases with age. Atrioventricular block as a part of diagnostic
criteria of KSS occurs in 84% of cases. KSS is defined by the
triad of pigmentary retinopathy, progressive external
ophthalmopathy, and onset before age 20 years old [98,
172]. Specific cardiac symptoms have been reported in nearly
60% of patients with KSS [173]. KSS develop fascicular
blocks, complete or partial right bundle branch block, com-
plete heart block, and nonspecific intraventricular conduction
delays [172]. Progression of atrioventricular block to its high
grade is often unpredictable which requires prompt identifica-
tion of this condition and early interventions. Early premature
death in cases with KSS is directly attributed to infra-nodal
block [174, 175]. The frequency of mutations in tissue is a
determining factor in the clinical manifestations of MIDs.
Excessive mutations and deletion in mtDNA in the His-
Purkinje system and AV node have been reported in a patient
with KSS after death, which is a reason for the sensitivity of
the conduction system to mtDNAmutation and mitochondrial
function [10]. Intra-atrial block (IAB) which is s a predictor of
atrial arrhythmia is observed in FA [176]. By early recognition
of IAB, asymptomatic FA patients who are susceptible to the
development of potentially life-threatening arrhythmia could
be identified [177]. In the patient with cardiac conduction
blocks, the placement of cardiac pacemaker is effective.
ECG and echocardiography surveillance every 6–12 months
is recommended in these cases. Application of antioxidants
could ameliorate injury derived by ROS [62].
Post-transplantation
For mitochondrial cardiomyopathy, heart transplantation is a
variable treatment. It should be noted that cardiac transplanta-
tion is absolutely contraindicated in cases with significant co-
morbid disorders [178]. Thus, the degree of extra-cardiac in-
volvement and predicted quality of life could be assessed
preoperatively. Some of the side effects after cardiac trans-
plantation could be related to their MELAS syndrome.
These patients are susceptible to the development of acidosis;
thus, maintenance of stable cardiovascular function is essen-
tial. Indeed, the administration of common cardiac drugs in
cases with MELAS syndrome needs lots of precaution due to
their possible disadvantages in MIDs like statins (reduced co-
enzyme Q), B-blockers (inhibited ATPase activity), and
acetylsalicylic acid (inhibited respiratory chain electron trans-
port). In addition, immunosuppressive drugs have not yet been
approved for MELAS syndrome. But despite of these obsta-
cles, some successful cases of heart transplantation in cases
with MIDs have been reported [178].
Arrhythmia
Torsade de points, as the mere manifestation of cardiac in-
volvement has been reported in a case of FA [178].
Sudden cardiac arrest
Neurological and cardiologic disorders are the major cause of
early death in MIDs cases with the m.3243A>G mutation. In
these cases, suspected sudden cardiac death has been frequent-
ly reported [179]. Cardiac involvement inMIDs is progressive
in nature. In fact, molecular events related to mtDNA defects
and cardiac disorders are not fully understood due to the low
frequency of the disorder, lack of access to human heart tissue,
and incompatibility of genotype and phenotype. Different car-
diac presentations may be seen in the specific mtDNA muta-
tions. Vice versa, different mitochondrial DNA (mtDNA) mu-
tations could be seen in the same cardiac presentations. Lack
of a reliable animal model is also a great obstacle. Thus, the
development of cardiomyocyte cell line derived from affected
patients might be useful and a step forward. Therefore, a deep
understanding of the range of clinical symptoms and genetic
causes of cardiac disorders in MIDs helps cardiologists to
properly manage patients [180].
Conclusion
Lack of unique cardiac phenotype and a variety of cardiac
complications of MIDs is a challenge for cardiologists.
Since early reports of cardiac involvement in MIDs depict a
phenotype with severe complications, early recognition of
cases with MIDs is essential. It has been notable that minor
ECG abnormalities are the most common cardiac manifesta-
tion. High-grade atrioventricular block and progression of sys-
tolic dysfunction occur in at least every 5 beats. But this can be
done by genetic screening of family to identify asymptomatic
or oligo-symptomatic adults. Finally, interdisciplinary
neurologic-cardiologic cooperation is required for the
Heart Fail Rev
treatment of most of MIDs. Fortunately, the management of
cardiac diseases related to MIDs is, as usual, cardiologist care,
but earlier recognition and close follow-up are essential. In
conclusion, the crucial problem that is associated with MIDs
is cardiac complications. More understanding about genetics
and epigenetics factors involved in MIDs that lead to cardiac
complications can provide new treatment strategies for the
management of MIDs.
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